WallStSmart
MGNX

MacroGenics Inc

NASDAQ: MGNX · HEALTHCARE · BIOTECHNOLOGY

$3.52
-8.00% today

Updated 2026-06-05

Market cap
$246.63M
P/E ratio
P/S ratio
1.57x
EPS (TTM)
$-1.11
Dividend yield
52W range
$1 – $5
Volume
1.0M

MacroGenics Inc (MGNX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201120122013201420152016201720182019202020212022202320242025
Operating cash flow$6.76M$-6.58M$-14.17M$-32.76M$-13.66M$-43.68M$14.40M$-153.23M$-134.27M$-111.90M$-143.83M$-86.96M$-78.20M$-68.37M$-81.04M
Capital expenditures$500213.00$940043.00$2.96M$3.57M$9.20M$11.38M$29.40M$24.95M$4.29M$5.91M$6.20M$3.62M$1.76M$3.71M$1.91M
Depreciation
Stock-based comp$2.35M$838395.00$862162.00$3.24M$7.85M$12.16M$14.74M$16.52M$19.57M$20.68M$23.13M$20.44M$18.37M$29.44M$14.29M
Free cash flow$6.26M$-7.52M$-17.13M$-36.33M$-22.86M$-55.06M$-15.00M$-178.19M$-138.56M$-117.80M$-150.03M$-90.58M$-79.97M$-72.08M$-82.95M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$0.00$0.00$0.00
Share repurchases
Debt repayment
Net change in cash$68.74M$41.11M$38.58M$-112.07M$127.63M$8.40M$54.66M$-57.66M$-14.59M

Frequently asked questions

What is MacroGenics Inc's revenue?

MacroGenics Inc's trailing twelve-month revenue is $157.08M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is MGNX?

In its most recent fiscal year, MGNX ran a gross margin of 71.12%, an operating margin of -48.72%, and a net margin of -49.91%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does MGNX generate?

MGNX produced $-82.95M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MGNX's balance sheet healthy?

MGNX holds $57.22M in cash and equivalents against — in long-term debt, on $55.59M of shareholder equity. That debt is best read against the cash flow the business throws off each year.